These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1002 related items for PubMed ID: 27845265

  • 1. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
    Yoon S, Kim J, Lee H, Lee H, Lim J, Yang H, Shin SS, Yoon M.
    J Ethnopharmacol; 2017 Jan 04; 195():204-213. PubMed ID: 27845265
    [Abstract] [Full Text] [Related]

  • 2. Herbal composition Gambigyeongsinhwan (4) from Curcuma longa, Alnus japonica, and Massa Medicata Fermentata inhibits lipid accumulation in 3T3-L1 cells and regulates obesity in Otsuka Long-Evans Tokushima Fatty rats.
    Roh JS, Lee H, Woo S, Yoon M, Kim J, Park SD, Shin SS, Yoon M.
    J Ethnopharmacol; 2015 Aug 02; 171():287-94. PubMed ID: 26068433
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.
    Yan F, Wang Q, Xu C, Cao M, Zhou X, Wang T, Yu C, Jing F, Chen W, Gao L, Zhao J.
    PLoS One; 2014 Aug 02; 9(6):e99245. PubMed ID: 24926685
    [Abstract] [Full Text] [Related]

  • 4. Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells.
    Zeng L, Tang W, Yin J, Feng L, Li Y, Yao X, Zhou B.
    Cell Physiol Biochem; 2016 Aug 02; 40(3-4):453-464. PubMed ID: 27889747
    [Abstract] [Full Text] [Related]

  • 5. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR, Yang HJ, Park KI, Ma JY.
    Phytomedicine; 2019 Mar 01; 55():14-22. PubMed ID: 30668424
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis.
    Cai D, Li Y, Zhang K, Zhou B, Guo F, Holm L, Liu HY.
    J Cell Physiol; 2021 Jun 01; 236(6):4387-4402. PubMed ID: 33184849
    [Abstract] [Full Text] [Related]

  • 8. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH, Chen TH, Lee BH, Hsu YW, Pan TM.
    Food Chem Toxicol; 2014 Feb 01; 64():94-103. PubMed ID: 24275089
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Therapeutic effects of granulocyte-colony stimulating factor on non-alcoholic hepatic steatosis in the rat.
    Song YS, Fang CH, So BI, Park JY, Jun DW, Kim KS.
    Ann Hepatol; 2013 Feb 01; 12(1):115-22. PubMed ID: 23293202
    [Abstract] [Full Text] [Related]

  • 11. Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes.
    Kang OH, Kim SB, Mun SH, Seo YS, Hwang HC, Lee YM, Lee HS, Kang DG, Kwon DY.
    Int J Mol Med; 2015 Mar 01; 35(3):803-9. PubMed ID: 25605057
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
    Rogue A, Anthérieu S, Vluggens A, Umbdenstock T, Claude N, de la Moureyre-Spire C, Weaver RJ, Guillouzo A.
    Toxicol Appl Pharmacol; 2014 Apr 01; 276(1):73-81. PubMed ID: 24534255
    [Abstract] [Full Text] [Related]

  • 18. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
    Zhao X, Xue J, Wang XL, Zhang Y, Deng M, Xie ML.
    Int Immunopharmacol; 2014 Sep 01; 22(1):176-81. PubMed ID: 24993341
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries.
    Liu Q, Pan R, Ding L, Zhang F, Hu L, Ding B, Zhu L, Xia Y, Dou X.
    Int Immunopharmacol; 2017 Aug 01; 49():132-141. PubMed ID: 28577437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.